Abstracts

Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma

Background It has been reported that the combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, and an immune checkpoint inhibitor enhances the antitu...

H. Nelson ;

Y. Kato ;

M. Kimura ;

M. Yamauchi ;

N. Suzuki ;

A. Ono ;

H. Aikata ;

K. Amioka ;

K. Chayama ;

Y. Fujii ;

S. Uchikawa ;

H. Fujino ;

T. Nakahara ;

E. Murakami ;

W. Okamoto ;

T. Kawaoka ;

D. Miki ;

M. Tsuge ;

M. Imamura ;

06/27/2022

Real-world data in patients with localized esophageal and gastro-esophageal junction cancer undergoing surgery in France: Results from the FREGAT database

Background Esophageal cancer (EC) is the third most common digestive cancer in France with an incidence of 5450 new cases in 2018. All stages combined the prognosis rema...

06/27/2022

Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study

Background The aim of the study was to examine the prognostic significance of inflammatory biomarkers in patients (pts) with locally advanced or metastatic pancreatic du...

06/27/2022

Using artificial intelligence CT-based methods to evaluate body composition for predicting survival outcomes in patients with colorectal cancer receiving PD-1 treatment

Background As for PFS, SMI [hazard ratio (HR) (95% CI): 1.041 ((1.003-1.081))], SMD [HR (95% CI): 1.113 (1.035-1.197)], and pre-therapeutic alkaline phosphatase (ALP) [H...

06/27/2022

Quality of life assessment in biliary tract cancer: A systematic review of phase 2 and 3 clinical trials published between 2010 and 2021

Background In the last decades quality of life (QoL) has emerged as a fundamental parameter in clinical trials to evaluate the impact of a drug, beyond traditional oncol...

06/27/2022

Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study

Background FOLFIRINOX represents the standard neoadjuvant chemotherapy regimen for patients with pancreatic ductal adenocarcinoma (PDAC). However, it is associated with ...

06/27/2022

The first comprehensive genomic characterization of rectal squamous cell carcinoma

Background Rectal cancers represent 35% of colorectal cancers; 90% are adenocarcinomas while rectal squamous cell carcinomas represents 0.3% of them. Given its rarity, l...

C. Astaras ;

C. De Vito ;

A. Bornand ;

A. Sciarra ;

K. Khanfir ;

I. Letovanec ;

P. Dietrich ;

P. Tsantoulis ;

T. Kossler ;

06/27/2022

Prognostic implication of portal venous circulating tumor cells in resectable pancreatic cancer

Background Circulating tumor cells (CTCs) may be promising prognostic biomarkers in patients with advanced cancer. However, the paucity of CTCs in peripheral blood is th...

S. Yoon ;

M. Choi ;

06/27/2022

Efficacy and safety of atezolizumab plus bevacizumab in unresectable or advanced hepatocellular carcinoma: Real life data from 5 Swiss centers

Background The landscape of systemic therapies (ST) for advanced hepatocellular carcinoma (HCC) pts has evolved in recent years. So far, the IMbrave 150 study (NCT034343...

06/27/2022

Real-world delivery, toxicity and outcomes of perioperative FLOT chemotherapy in resectable gastric/gastroesophageal adenocarcinoma: A population-based study

Background Perioperative docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) has become the new standard of care for resectable gastric/ gastroesophageal adenocarc...

06/27/2022